Mediran (Ranitidine)

Ranitidine blocks histamine H2 receptors on the surface of gastric parietal cells. By competitively inhibiting these receptors, it prevents histamine‑stimulated activation of the proton pump, thereby reducing the volume and acidity of gastric secretions.

The specific dose of Mediran is determined by the prescribing clinician based on the patient’s condition, age, renal function and other individual factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for ranitidine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Mediran, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ranitidine belongs to the H2‑receptor antagonist class, which reduces acid production by a different mechanism than proton‑pump inhibitors (PPIs). Compared with PPIs, ranitidine generally has a faster onset but a shorter duration of action, and it may be preferred when rapid symptom relief is needed or when PPIs are contraindicated.

Mediran should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Mediran is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or broken unless specifically instructed.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, blood‑cell abnormalities like thrombocytopenia or neutropenia, and anaphylactic reactions. Patients should seek immediate medical attention if they experience rash, jaundice, unusual bruising, or difficulty breathing.

Mediran is contraindicated in individuals with known hypersensitivity to ranitidine or any component of the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in those taking drugs that have major contraindicated interactions unless closely monitored.